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The inununologic aberrations associated with atopic 
dermatitis include the paradox of reduced cell-medi­
ated immune responses in the setting of increased 
cell-mediated immunity features that resemble aller­
gic contact dermatitis. In this review, we present 
evidence that abnormalities in monocytes and Lan­
gerhans cells alter the function ofT-helper-cell sub­
populations to cause the immunologic defects asso­
ciated with atopic dermatitis. Increased monocyte 
prostaglandin E2 production inhibits Thl responses, 
accentuating interleukin (IL)-4 secretion by Th2 
cells. Elevated prostaglandin E2 secretion correlates 
with abnormally increased cyclic adenosine mono­
phosphate-phosphodiesterase activity in monocytes 
and this, along with other defective in1l.ammatory 
P erhaps the earliest report linking atopic dermatitis and altered cell-mediated immunity was Kaposi's descrip­tion, in 1896, of eczema herpeticum (Kaposi's varicel­liform eruption) [1]. We now realize that this condition reflects an increased susceptibility to spreading cutane­
ous Herpes simplex virus infection. In 1937, Becker described the 
subnormal responsiveness of atopic patients to poison ivy [2], and 
these observations have been confirmed experimentally with dini­
trochlorobenzene cutaneous testing [3]. Studies in the 1970s dem­
onstrated reduced in vitro lymphocyte responses to antigens and 
mitogens [4-7]. 
The advent of immunocytochemistry uncovered the paradox 
that, despite the depressed cell-mediated immunity in atopic der­
matitis, histologically there is a predominance of CD4 + T cells 
along with features indistinguishable from allergic contact derma­
titis [8]. More recent studies have suggested that the resolution of 
this paradox may require a better understanding of the dynamics of 
T-cell subpopulations. The actual role ofT cells in atopic dermatitis 
remains confusing. Evidence for T-cell activation includes in­
creased expression of activation markers on dermal CD4 + cells 
[8,9], elevated interleukin (IL)-2 receptor levels in serum [10], and 
increased spontaneous production of IL-6 [11]. Direct in vitro 
measurements of spontaneous tritiated thymidine uptake have 
failed to demonstrate evidence oflymphocyte activation [6,7]. 
There is no evidence that T cells act as effector cells in the 
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cell responses, can be normalized in vitro by phos­
phodiesterase inhibitors. It appears that in addition 
to prostaglandin E2, IL-l0 acts to regulate the balance 
between Thl and Th2 functional responses account­
ing for many atopic features, including increased 
IL-4, IL-5, and IL-6 production by T cells; increased 
IgE synthesis; decreased interferon-1' production; 
and impaired cell-mediated immune responses. All of 
these abnormalities can be related to increased phos­
phodiesterase activity in atopic monocytes, and inhi­
bition of this key enzyme appears to reverse atopic 
dermatitis inflanunatory abnormalities in vitro and ill 
vivo. Key words: cell-mediated immunity/intevferon-1'/Lan­
gerhans cells/mononuclear leukoCJItes. J Invest Devmatol1 OS: 
848-888, 1995 
pathogenesis of atopic dermatitis lesions. Eosinophils, detected by 
antibodies against specific cationic proteins such as major basic 
protein, seem more likely to serve an effector function [12]. These 
cells appear to infiltrate lesional areas early and then disintegrate, 
releasing the highly toxic, inflammation-producing cationic pro­
teins. The relevance of mast cells and basophils in chronic eczem­
atous lesions is questionable [13]. Likewise, neutrophils, prominent 
in late-phase reactions, are conspicuous by their absence in atopic 
dermatitis lesions [14]. 
In recent years, increasing interest has focused on atopic derma­
titis lesional cells of the mononuclear phagocyte lineage, including 
Langerhans cells and monocytes, both of which may gready 
influence the character and function of lymphocytes and cytokines 
in atopic disease. We have observed several lines of evidence 
suggesting that biochemical defects in monocytes are responsible 
for many of the immunologic and inflannnatory features of atopic 
dermatitis. 
MONOCYTE PROSTAGLANDIN (PG) E2 EFFECTS 
The immunologic influence of abnormal monocyte function was 
demonstrated by studies measuring interferon (IFN)--y production. 
Our initial results [15] confirmed those of Reinhold et al [16], 
showing reduced IFN--y production by atopic dermatitis peripheral 
blood mononuclear leukocytes (MNL) in vitro (Fig 1): However, 
after we removed the monocytes from MNL preparations and then 
isolated the purified T cells, the atopic dermatitis lymphocyte 
preparations produced significantly greater IFN--y (Fig 1). This 
indicated that an inhibitory factor present in atopic MNL had been 
removed by the T-cell purification process. Because Betz and Fox 
[17] had recently shown that PGE2 inhibited IFN--y production in 
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Figure 1. IFN-y production by normal and atopic dermatitis (AD) 
MNL and T cells. FicoU-separated MNL (dotted bars; n = 5) or column­
purified T ceUs [15] (striped bars; n = 14) at 2 X 10· cells/ml were incubated 
in RPMI plus 10% fetal bovine serum for 24 h at 37°C in the presence or 
absence of phorbol myristate acetate (500 ng/ml) plus ionophore A23187 
(100 ng/ml). The supernatants were collected, and IFN-y was measured by 
enzyme-linked immunosorbent assay [15]. Significant dllferences between 
normal and atopic dermatitis supernatant IFN-y levels are indicated by 
asterisks: *p = 0 .028; **p = 0.008. Bars, SEM. 
murine T-cell clones, we next compared PGE2 production in atopic 
dennatitis and nonnal MNL cultures and found that spontaneous 
PGE2 release was significantly higher in the atopic dennatitis 
preparations (p = 0.014, n = 9; Fig 2). Preliminary data show that 
the monocyte is the source of the increased PGE2 secretion. * This 
PGE2 effect was inhibitable with indomethacin, which greatly 
increased IFN-1' production in atopic dennatitis but not in nonnal 
MNL cultures [15]. Although indomethacin increased IFN-1' pro­
duction, IL-4 production was not suppressed in these MNL cul-
* Chan SC, HanifinJM: Phosphodiesterase inhibitor modulation ofIL-4 
production in atopic dermatitis is monocyte-derived PG�-dependent (ab­
str). Skin Phannacol 7:154, 1994. 
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Figure 2. PGE. production by normal and atopic dermatitis (AD) 
MNL. Spontaneous PGE2 (pg/ml) production [15] by normal and atopic 
dermatitis MNL in 24-h cultures (p = 0.014, n = 9). 
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Figure 3. Frequency histogram showing the range of MNL PDE 
activities. PDE activity (1 U = pmol/min/ f.Lg) was compared with the 
number of subjects (frequency count at each interval) [19] in 42 normals 
(dotted bars) (0.0274 ± 0 .002) and 39 patients with atopic dermatitis (solid 
bars) (0.165 ± 0.017). PDE activities were determined as described [19]. 
Bars, SEM. 
tures. This indicated that IFN-1' alone does not reduce IL-4 and that 
the Th1/Th2 balance is influenced by factors other than PGE2• 
These studies demonstrated that atopic dermatitis monocytes 
produce increased PGE2, which in tum inhibits T-cell IFN-1' 
production. As noted below, recent evidence indicates that atopic 
dermatitis monocytes produce increased amounts ofIL-10, which 
also is inhibitory for IFN-1' production by Th1 cells. These and 
other monocyte-derived inhibitory factors may cause a functionally 
relevant IFN-1' deficiency, which may account for the reduced 
cell-mediated immune responses in the skin of patients with atopic 
dermatitis. Reversing this monocyte-imposed Th1/Th2 imbalance 
may be a mechanism by which recombinant IFN-1' therapy reduces 
inflammation in patients with severe atopic dermatitis [18]. 
CYCLIC NUCLEOTIDE ABNORMALITmS 
We questioned whether there was a relation between increased 
atopic dermatitis monocyte PGE2 production and our previously 
demonstrated elevation of cyclic adenosine monophosphate 
(cAMP)-phosphodiesterase (PDE) activity [19]. These monocyte 
cyclic nucleotide abnormalities in atopic dermatitis came to light 
through separate lines of investigation, based on the hypothesis that 
there must be a link between the immunologic and cyclic nucle­
otide defects in leukocytes from patients with atopic dermatitis. 
Early studies had demonstrated that immunologic abnormalities in 
atopic dermatitis were inconsistent and varied with severity of the 
disease [1,4], leading us to investigate the more consistent and 
fundamental leukocyte cAMP abnormalities present in atopic der­
matitis. 
We found that atopic MNL manifested subnormal cAMP re­
sponses to adenylyl-cyclase-activating agonists such as isoprotere­
nol, histamine, and PGs [20]. This abnormality was shown to be 
due to increased cAMP hydrolysis by PDE [19]. The increased PDE 
activity has been very consistent among patients with atopic 
dermatitis, and little overlap has been detectable in normal subjects 
who were carefully selected for the absence of a personal or tiunily 
history of atopic disease (Fig 3). In our original studies [19], we 
found that patients with allergic respiratory disease likewise had 
elevated PDE activities, whereas nona topic patients with wide­
spread allergic contact dermatitis had levels in the normal range. 
We also demonstrated elevated umbilical cord blood leukocyte 
PDE activity in infants whose parents had atopic disease [21], 
suggesting a genetic basis for this abnormality. 
The major component of the elevated enzyme activity in MNL 
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Table I. Spontaneous Production of JL.6 and JL.4 by 
Normal and Atopic Dermatitis T Cells in 24-h Cultures· 
Atopic dennatitis 
Normal 
IL-6 (U/mJ) 
36.1 ± 5.1 (n = 22) 
12.6 ± 1.9 (n = 22) 
IL-4 (U/ml) 
BDb (n = 14) 
BDb (n = 14) 
• T cells were cultured in RPM! medium plus 10% fetal bovine serum for 24 h at 2 
X 106 cells/mI. Supernatants were harvested and assayed for IL-4 by enzyme-linked 
immuno,orbent assay [27] and for IL-6 by B9 bioassay [11]. Cytokine units are 
expressed as mean ± SEM. The levels of IL-6 were significantly different between 
atopic dermatitis and the normal preparation (p = 0.0027). 
b Below the detection level. 
was found in adherent monocytes [22]. Comparisons of enzyme 
isoforms in lymphocytes and monocytes showed distinct fractions 
that were much more active than PDEs in normal leukocytes 
[23,24]. 
Functional consequences of elevated PDE in atopic dermatitis 
include increased basophil histamine release [25] and elevated 
spontaneous IgE production [26]. These studies indicated that 
abnormal PDE activity may influence multiple cell types, including 
basophils, mast cells, and B lymphocytes, as well as monocytes. 
Recently, we have shown correlations between high PDE activity 
and increased T-cell production of IL-4 by peripheral blood MNL 
[27]. Each of these biologic function studies showed reversal of the 
abnormality with PDE inhibitors, especially type IV inhibitors such 
as Ro 20-1724 [25-27]. In addition, a recent study by Shute et al 
[28] demonstrated increased chemotaxis by atopic eosinophil. that 
showed greater sensitivity to PDE inhibitors. This is a general 
characteristic of atopic leukocyte PDE isoenzymes, which consis­
tently show increased inhibition by a variety of agents [29]. These 
inhibitors have an increased therapeutic window in atopic cells, and 
they provide a new approach to anti-inflammatory therapy of atopic 
disease. 
In addition to the PGE2 and cyclic nucleotide abnormalities 
associated with atopic dermatitis monocytes, others have shown 
increased CD23 expression and elevated superoxide generation by 
these cells [30]. Considerable interest has also focused upon a 
possible role of Langerhans cells in atopic dermatitis. Both mono­
cytes and Langerhans cells have increased expression of the high­
affinity 19B receptor (FcElU) in atopic dermatitis [31]. Two different 
studies have suggested Langerhans cells abnormalities in atopic 
dermatitis, one showing increased aeroallergen-specific IgE-depen­
dent antigen-presenting capacity [32] and another showing that 
lesional Langerhans. cells were hyperstimulatory for autologous T 
lymphocytes [33]. All of these studies indicate that cells of the 
monocyte/macrophage lineage have an important role in atopic 
dermatitis and that abnormalities of PDE and cyclic nucleotide 
metabolism may be central to the dysfunction of these cells. 
MONOCYTE MODULATION OF T-CELL RESPONSES 
Having demonstrated a relation between altered monocyte cyclic 
nucleotide metabolism, increased PGE2 secretion, and reduced Th1 
production of IFN-y in atopic dermatitis, we questioned whether 
the monocyte abnormalities might also aif"ect cytokine production 
by Th2 cells. We have previously reported increased spontaneous 
T-cell production ofIL-6 [11] by atopic monocytes, but we have 
found spontaneous production ofIL-4 below the detectable level of 
the enzyme-linked immunosorbent assay (Table I). PGEz eif"ected 
an increase in IL-6 activity in atopic dermatitis compared with 
normal cells in both unstimulated and phorbol myristate acetate/ 
ionophore-stimulated cultures (Fig 4). PGEz also caused a dose­
related increase in IL-4 production by atopic T cells. t However, 
these eif"ects required one to two log higher concentrations ofPGE2 
than was required to inhibit IFN-y, leaving uncertain the biologic 
t Shen K, DeMay M, Chan S, Hanifin JM: Monocyte prostaglandin E2 
regulates intcrleukin 4 and interferon-gamma production in atopic denna­
titis (abstr).] Illvest Dermatoll02:631, 1994. 
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Figure 4. IL-6 activity in nonnal and atopic dennatitis subjects 
with and without stimulation. T-cell IL-6 bioactivity (B-9 proliferation 
assay measured in cpm [11]) comparing leukocyte supernatants grouped at 
0.05-U intervals from a single normal subject (solid bars) and a patient with 
atopic dennatitis (sMpped bars), either unstimulated or treated with PGE2 for 
24 h. PMA, phorbol myristate acetate. 
relevance of this observation. However, recent evidence suggests 
that this PGE2 effect requires exogenous IL-2 ill vitl·o and that the 
cellular interaction may be quite complex, possibly relating to the 
mechanism by which IL-2 stimulates IL-4 production in naive T 
cells [34,35]. The combination of findings caused us to speculate 
that excessive atopic dermatitis monocyte PGE2 shifts the Th1/1b2 
ratio toward increased Th2 eif"ects and decreased IFN-y production. 
The mechanism for this shift could occur either by altering the 
quantities of cytokines from a given population of T cells or by 
influencing the numbers of cells in the Th1/Th2 subpopulation. 
In support of the latter mechanism, we have recendy demon­
strated that IFN-y normalized phytohemagglutinin-stimulated 
atopic dermatitis lymphocyte proliferation whereas IL-4 was inhib­
itory for normal cells (Fig 5). The proliferation index correlated 
closely with increased IFN-y and with decreased IL-4 production in 
parallel cultures. Comparing IFN-y production with PDE activity, 
we found an inverse correlation, whereas IL-4 production corre­
lated directly in atopic MNL.:j: These findings may account for our 
previous study showing reduced lymphocyte proliferation in atopic 
dermatitis [7] and further support the role of monocyte PDE in the 
cytokine defects associated with atopic dermatitis. 
EFFECT OF PDE INHIBITORS 
In previous studies of leukocytes from patients with atopic derma­
titis, we found direct correlations between increased PDE activity 
and both basophil histamine release [26] and B-cell IgE production 
[27]. Both of these parameters were normalized by addition of the 
type IV PDE inhibitor Ro 20-1724. More recently, we have shown 
that this and other PDE inhibitors reduce the increased IL-4 
production by atopic T cells [27}, probably accounting for the 
eaQier observations on IgE production. These inhibitors had no 
effect on normal IL-4 production. We have also shown both ill vitro 
and in vivo eif"ects of IFN-y as a PDE inhibitor in monocytes from 
patients with atopic dermatitis, eif"ects not found in normal donors 
[36]. Recent studies by Shute et al [28] likewise showed an 
augmented PDE inhibitor eif"ect on atopic eosinophil chemotaxis. 
All of these results are consistent with our direct enzyme assays 
showing that atopic PDE isozymes have much greater sensitivity to 
a variety of PDE inhibitors [29,37], clearly demonstrating a 
:j: Chan SC, Li SH, Hanifin JM: III vitro interferon-gamma restoration of 
type 1 T cell growth rate in atopic dermatitis (abstr).] Invest Dermotol 
100:489, 1993. 
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Figure S. Lyntphocyte proliferation in nonnal and atopic denna­
titis subjects upon stimulation with phytohemagglutinin (PHA), 
and effects oflFN-y and IL-4. Phytohemagglutinin-stimulated prolifer­
ation CHTdR uptake) in MNL 24-h cultures from patients with atopic 
dermatitis (closed circles; n = 3) and normal subjects (open squares; n = 3), 
comparing the effects of IFN-y (dashed line) and llA (dotted line). Basal, 
unstimulated proliferation was similar in normal and atopic dermatitis 
cultures and was not influenced by cytokines . Cultures were maintained in 
RPMl/15% fetal bovine serum with or without phytohemagglutinin 
(0.D1-10 JLg/ml), IFN-y (100 ng/rul), or IL-4 (100 U/ml). Cells were then 
harvested and counted 8 h after addition of 3H-thymidine to give cpm ± 
SEM. 
uniquely greater therapeutic window for the treatment of atopy. 
This, combined with the elfects of POE inhibitors on histamine 
release, PGE2 secretion, and cytokine production in multiple 
immune and inflammatory cells, suggests that POE inhibitors have 
considerable potential in the therapy of atopic dermatitis and atopy 
in general [27]. In fact, recent studies have shown efficacy for POE 
inhibitors in treating atopic dermatitis.§ 
In this brief overview, we have presented evidence that increased 
PDE activity in atopic dermatitis monocytes causes increased PGE2 
production, which in turn inhibits IFN-y production by atopic T 
cells. It appears that monocytes can modulate the balance between 
Thl and Th2 populations, possibly by alfecting lymphocyte prolif­
eration [38], by regulating cytokine production, or both (Fig 6). 
We do not believe that PGE2 is the only monocyte mediator 
alfecting lymphocyte function in atopic dermatitis. In fact, a recent 
collaboration [39] has provided evidence for increased IL-IO 
production by atopic dermatitis monocytes, and this cytokine may 
likewise have a considerable elfect on Thl/Th2 balance, at least in 
part by inhibiting IFN-/, production. Thus. at least two and possibly 
multiple monocyte and dendritic cell factors may cause dysregula­
tion of lymphocyte function in atopic dermatitis, alfecting cell­
mediated immune responses and predisposing to the prolonged 
inflammatory reactions characteristic of atopic dermatitis. Finally, 
we have developed evidence that POE inhibitors have dilferential 
action on multiple atopic dermatitis inflammatory cells and path­
ways. This may have considerable therapeutic potential for atopic 
dermatitis and, we hope. for other inflammatory diseases as well. 
§ Hanifin JM, Tofte SJ: Unpublished observation. 1994. 
Figure 6. Proposed mechanism of PDE abnonnalities in atopic 
dennatitis. Elevated cAMP-PDE in atopic monocytes causes reduced 
cAMP responses leading to greater release of mediators (e.g .• PG� and 
IL-l0). which act On uncommitted T-helper cells (THO) to reduce Thl 
function (e .g. ,  IFN-y production) and increase Th2 cytokines (e.g .• IL-4 
and 11.-5). This process leads to atopic features such as increased IgE 
production and eosinophilia. G, GTP-bihding proteins regulating adenylyl 
cyclase. 
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